---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-24-059322"
form_type: "8-K"
ticker: "IOVA"
cik: "0001425205"
company_name: "IOVANCE BIOTHERAPEUTICS, INC."
filed_at: "2024-05-09T23:59:59+00:00"
generated_at: "2026-06-02T05:22:54.724044+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.78
calibrated_materiality_score: 0.78
confidence: "high"
source: SEC EDGAR
---

# Iovance reports Q1 net loss $113M; Amtagvi launch strong with 100+ patients enrolled across 40+ ATCs

## Summary
- Net loss $113.0M ($0.42 per share) vs $107.4M ($0.50) YoY; revenue $0.7M from Proleukin sales.
- Cash, equivalents & investments $362.6M vs $346.3M at Dec 31, 2023; runway into H2 2025.
- More than 100 patients enrolled for Amtagvi since Feb 16 FDA approval; ~50 ATCs on track by end of May, 70+ by year-end.
- Manufacturing turnaround ~34 days; >75% of enrolled patients covered by private payers.
- Regulatory filings for lifileucel on track in EU (Q2 2024), UK/Canada (H2 2024), Australia (2025).

## SEC filing metadata
- accession: 0001104659-24-059322
- form_type: 8-K
- ticker: IOVA
- cik: 0001425205
- company_name: IOVANCE BIOTHERAPEUTICS, INC.
- filed_at: 2024-05-09T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.78
- calibrated_materiality_score: 0.78
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1425205/000110465924059322/0001104659-24-059322-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1425205/000110465924059322/tm2413980d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-24-059322
- JSON: https://secwatch.observer/filing/0001104659-24-059322.json
- Plain text: https://secwatch.observer/filing/0001104659-24-059322.txt

## Key facts
- Earnings Releases
  IOVANCE BIOTHERAPEUTICS, INC. reported financial results for first quarter 2024.
  - Period: first quarter 2024
  - Result: reported results
  source text: On May 9, 2024, Iovance Biotherapeutics, Inc. (the “Company”) issued a press release announcing its financial results for the first quarter ended March 31, 2024
  evidence_url: https://www.sec.gov/Archives/edgar/data/1425205/000110465924059322/0001104659-24-059322-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.